Status and phase
Conditions
Treatments
About
In this study, our aim is to investigate the role tranexamic acid in modulating inflammation in patients with sepsis.
Full description
A written informed consent will be taken from the patients or their relatives.Patients will be assigned randomly to two groups (40 subjects each) with qSOFA ≥2.
In (Group T) administer 1 gram of tranexamic acid (TXA) in 100 ml of 0.9% normal saline, intravenous over 10 minutes as soon as possible but no later than three hours after diagnosis, infuse a second gram of tranexamic acid (TXA) IV over 8 hours in 0.9% normal saline for the first 3 days. In (Group C) administer the same volume (100 ml normal saline)and same duration (first three days)for controlled patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
80 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Omar Soliman
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal